PAK2 Antibody (YA5004)

PAK2 (p21-activated kinase 2) is a ubiquitously expressed serine/threonine kinase of the group I PAK family that functions as a major downstream effector of the small GTPases CDC42 and RAC1, linking Rho GTPase signaling to cytoskeletal remodeling and nuclear signaling pathways^[1][2]. PAK2 activation is mediated through release of autoinhibition within its regulatory domain, followed by autophosphorylation and kinase activation, enabling regulation of cell adhesion, actin dynamics, cell division, apoptosis, and intracellular signal transduction^[2]. Mechanistically, PAK2 participates in multiple signaling networks and can modulate transforming growth factor-β (TGF-β) responses by restricting R-Smad phosphorylation and transcriptional activity, highlighting its role in signal integration and cellular homeostasis^[3]. In disease-related contexts, aberrant PAK signaling has been associated with cancer progression, cell survival, migration, and cytoskeletal reorganization, making PAK family members important subjects in experimental oncology research^[4]. Compared with the closely related isoforms PAK1 and PAK3, PAK2 is distinguished by its ubiquitous expression pattern and its requirement for embryonic development, whereas PAK1 shows more restricted adult tissue expression and PAK3 is predominantly expressed in the brain^[2]. Notably, PAK2 is the only PAK family member directly activated by caspase-3-mediated proteolytic cleavage, generating a constitutively active kinase fragment that contributes to apoptotic signaling and cellular stress responses. For experimental applications, small-molecule group I PAK inhibitors such as FRAX597 have been widely used to suppress PAK activity and investigate PAK-dependent signaling mechanisms in tumor and cell biology models^[2].